Market Capitalization Summary - New Oriental has a market capitalization of 16.359 billion [2] - TAL Education has a market capitalization of 10.938 billion [2] - Vipshop has a market capitalization of 6.578 billion [2] - Miniso has a market capitalization of 5.578 billion [2] - Zai Lab has a market capitalization of 3.982 billion [2] - Huya has a market capitalization of 0.724 billion [3] Stock Performance - New Oriental's stock increased by 0.77 (+3.89%) [2] - TAL Education's stock decreased by 0.04 (-0.82%) [2] - Vipshop's stock decreased by 0.18 (-1.19%) [2] - Miniso's stock decreased by 0.50 (-2.62%) [2] - Zai Lab's stock decreased by 1.95 (-5.16%) [2] - Huya's stock increased by 0.01 (+0.45%) [3] Additional Company Insights - Financial One Account has a market capitalization of 0.287 billion [3] - Xiaomi has a market capitalization of 0.213 billion [3] - Huami has a market capitalization of 0.175 billion [3] - Tuniu has a market capitalization of 0.120 billion [3]

Core Viewpoint - Tianjing Bio (IMAB) has shown significant stock price movement and financial performance, indicating potential growth in the biopharmaceutical sector focused on innovative therapies for cancer and autoimmune diseases [1][2]. Financial Performance - As of December 31, 2023, Tianjing Bio reported total revenue of 27.644 million RMB, representing a year-on-year increase of 112.48% [1]. - The company recorded a net profit attributable to shareholders of -1.466 billion RMB, which is a 41.54% increase compared to the previous year [1]. Upcoming Events - Tianjing Bio is scheduled to disclose its fiscal year 2024 mid-term report on August 28, 2023, before the market opens in the Eastern US [2]. Company Overview - Tianjing Bio is an offshore holding company that operates through its domestic subsidiary, focusing on innovative biopharmaceuticals in the fields of tumor immunology and autoimmune diseases [2]. - The company's mission is to develop groundbreaking innovative biopharmaceuticals that address unmet clinical needs and improve the quality of life for patients globally [2].

Core Viewpoint - Everest Medicines has made a strategic equity investment of US$30.9 million in I-Mab, acquiring a 16.1% ownership stake, which aligns with its focus on next-generation oncology programs and enhances its presence in the U.S. market [1][4]. Investment Details - The investment will be made through the subscription of 15,846,154 American Depositary Shares (ADSs) at an offering price of $1.95 per ADS, contributing to total gross proceeds of approximately US$65 million for I-Mab [5]. - Following the investment, Everest will hold a total of 15,846,154 ADSs and 6,078,571 ordinary shares of I-Mab, representing approximately 16.1% of I-Mab's total issued share capital [5]. Clinical Development Synergies - I-Mab's bispecific antibody pipeline, particularly the 4-1BB receptor targeting platform, is complementary to Everest's existing mRNA cancer vaccines and in vivo CAR-T platform, potentially accelerating the development of pipeline products for both companies [2][3]. - The collaboration may leverage I-Mab's clinical translational capabilities in the U.S. and Everest's clinical capabilities in Asia, enhancing the global expansion of their respective product pipelines [3][4]. Product Pipeline - I-Mab's key pipeline products include Givastomig (Claudin 18.2 x 4-1BB bispecific antibody), which has shown an overall response rate (ORR) of 83% in a Phase 1b trial for first-line gastric cancers [1][9][13]. - Other notable candidates in I-Mab's pipeline include Ragistomig (PD-L1 x 4-1BB bispecific antibody) and Uliledlimab (CD73 antibody), indicating a strong focus on precision immuno-oncology agents [8][13]. Company Background - Everest Medicines is a biopharmaceutical company dedicated to discovering, developing, and commercializing innovative therapeutics, particularly in oncology, renal diseases, infectious diseases, and autoimmune disorders [11]. - I-Mab is a U.S.-based global biotech company focused on precision immuno-oncology, with a differentiated pipeline aimed at treating various cancers [8][13].

Group 1 - Company Gindalbie Metals announced the acquisition of 15.84 million American Depositary Shares (ADS) of I-Mab at a price of $1.95 per ADS, totaling approximately $30.9 million [1] - Following the acquisition, the company will hold a total of 15.84 million ADS and 6.08 million ordinary shares, representing about 16.1% of I-Mab's total issued share capital post-transaction [1] - The company focuses on innovative drug and vaccine research and development, with a strategic pipeline of promising clinical-stage products aimed at addressing unmet medical needs globally [1] Group 2 - I-Mab is a global biotechnology company headquartered in the United States, specializing in precision immuno-oncology drugs for cancer treatment [2] - I-Mab has three clinical-stage pipeline products, including Givastomig, Ragistomig, and Uliledlimab, which are designed to target specific cancer markers [2] - The board believes that the acquisition will enhance I-Mab's unique capabilities in clinical translation, particularly in the U.S., and complement the company's existing investments in mRNA cancer vaccines [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴該 等內容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立的有限公司） （股份代號：1952） Everest Medicines Limited 雲 頂 新 耀 有 限 公 司 自願性公告 本公告由雲頂新耀有限公司（「本公司」）自願作出。 本 公 司 董 事（「 董 事 」）會（「 董 事 會 」）宣 佈 ， 於 2025 年 8 月 1 日 ， 本 公 司 認 購 I -Mab （「 I -M a b 」）（ 一 間 於 納 斯 達 克 全 球 市 場 上 市 之 公 司 ， 股 份 代 號 為「 IM AB 」）之 15,846,154股美國預託股份（「ADS」）（ 每十(10)股ADS相當於二十三(23)股普通股 ） （「認購事項」），每股ADS為1.95美元（ 相當於約每股ADS 15.3港元 ）。認購事項之 總代價為30.9百萬美元（ 相當於約242.6百萬港元 ）。認購事項完成後，本公司將合 共持有15,846,154股ADS ...

ROCKVILLE, Md., Aug. 01, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced the pricing of an underwritten offering in the United States of 33,333,334 American Depositary Shares (ADSs) representing 76,666,668 ordinary shares at an offering price of $1.95 per ADS, for total gross proceeds of approximately $65 million. All of the ADSs to be sold in the off ...

Market Capitalization Overview - New Oriental has a market capitalization of 15.747 billion [2] - TAL Education (好未来) has a market capitalization of 11.040 billion [2] - Vipshop (唯品会) has a market capitalization of 9.610 billion [2] - Miniso (名创优品) has a market capitalization of 5.940 billion [2] - Zai Lab (再鼎医药) has a market capitalization of 4.200 billion [2] - Huya (虎牙) has a market capitalization of 7.500 billion [2] Stock Performance - New Oriental's stock increased by 0.36 (+8.09%) [2] - TAL Education's stock decreased by 0.27 (-0.60%) [2] - Vipshop's stock increased by 0.56 (+2.49%) [2] - Miniso's stock increased by 0.01 (+0.07%) [2] - Zai Lab's stock decreased by 0.81 (-4.06%) [2] - Huya's stock increased by 0.03 (+0.75%) [2] Additional Company Insights - Financial One Account (金融壹账通) has a market capitalization of 2.91 million [3] - Xunlei (迅雷) has a market capitalization of 4.48 million [3] - Huami Technology (华米科技) has a market capitalization of 1.64 million [3] - Tuniu (途牛) has a market capitalization of 1.21 million [3] - Aiqiyi (爱奇艺) has a market capitalization of 24.11 billion [2]

7月31日，天境生物(IMAB)开盘上涨19.41%，截至21:30，报2.03美元/股，成交375.47万美元，总市值 1.66亿美元。 8月28日，天境生物(美东)盘前披露2024财年中报（数据来源于纳斯达克官网，预计披露日期为美国当 地时间，实际披露日期以公司公告为准）。 资料显示，天境公司是一家境外注册成立的离岸控股母公司,通过境内子公司天境生物开展业务。天境 生物是一家聚焦于肿瘤免疫和自身免疫领域的创新生物药企业,公司高度专注于在全球范围内开发具 有"全球首创"和"同类最优"潜力的创新生物药。公司的使命是研制具有突破性的创新生物药,填补临床 治疗需求的空白,并且切实提高全球患者的生存质量。为了实现这个目标,公司正在努力成为一家扎根中 国、面向全球的领先生物医药公司。 本文源自：金融界 作者：行情君 财务数据显示，截至2023年12月31日，天境生物收入总额2764.4万人民币，同比增长112.48%；归母净 利润-14.66亿人民币，同比增长41.54%。 大事提醒： ...

| 代码 | 名称 | 最新价 | 涨跌幅√ | 涨跌额 | 成交额 | | --- | --- | --- | --- | --- | --- | | JEM | 707 Cayman Holdings | 5.935 | 41.31% | +1.735 | 275.65万 | | AACG | ATA Creativity Global | 1.700 | 33.36% | +0.425 | 81.89万 | | RCON | 研控科技 | 2.720 | 20.35% | +0.460 | 2004.51万 | | CNTB | 康乃德午物 | 2.100 | 20.00% | +0.350 | 56.51万 | | IMAB | I-Mab | 2.030 | 19.41% | +0.330 | 376.52万 | 中概股收盘涨幅前五的个股为：707 Cayman Holdings涨41.31%，ATA Creativity Global涨33.36%，研控 科技涨20.35%，康乃德生物涨20%，I-Mab涨19.41%。(格隆汇) ...

Market Capitalization Summary - New Oriental has a market capitalization of 15.98 billion [2] - MIN (Ming Chao) has a market capitalization of 10.21 billion [2] - TAL has a market capitalization of 9.38 billion [2] - The market capitalization of various companies includes: - 7.77 billion for Grape Fang [2] - 6.21 billion for Yi Pin Hui [2] - 4.28 billion for Zai [2] - 3.83 billion for Huya [2] Stock Performance - New Oriental's stock increased by 0.28 (+1.45%) [2] - MIN's stock decreased by 0.20 (-4.25%) [2] - TAL's stock decreased by 0.15 (-0.69%) [2] - Grape Fang's stock decreased by 2.39 (-5.11%) [2] - Yi Pin Hui's stock increased by 0.38 (+1.94%) [2] - Zai's stock decreased by 0.10 (-0.93%) [2] Additional Company Insights - The market capitalization of various companies shows a diverse range, with some experiencing significant fluctuations in stock prices [2] - Companies like Huami and Cheetah Mobile have market capitalizations of 1.76 billion and 1.73 billion respectively, with varying stock performance [4] - The overall market trends indicate a mix of gains and losses across different sectors, reflecting the volatility in the market [4]